Skip to main content
Premium Trial:

Request an Annual Quote

PE, Applera, Matrix Technologies, Nanogen, Affymetrix, Bio Merieux, Affymetrix


PE and Applera have received US Patents No. 6,492,156-6,492,153, “Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof.” The patents cover a system for isolated peptide and nucleic acid molecules, methods of identifying orthologs and paralogs of the kinase peptides, and methods of identifying modulators of the kinase peptides as well as microarrays for nucleic acid detection. The technology provides novel peptides and proteins that affect protein phosphorylation and nucleic acid molecules encoding such peptide and protein molecules, all of which are useful in the development of human therapeutics and diagnostic compositions and methods.

Matrix Technologies of Hudson, N.H., has received US Patent No. 6,492,118, “Methods of immobilizing ligands on solid supports.” The patent covers a technology for immobilizing a ligand on a solid support substrate.

Nanogen has received US Patent No. 6,492,122, “Quantitative analysis methods on active electronic microarrays.” The patent covers a method for gene expression monitoring and normalizing the signals of individual microlocations by the use of an internal control sequence probe. The technology provides for a way to generate mRNA expression samples from populations of cells, tissues, or other biological source materials, that may differ in their physiological and/or pathological state. and generating a reusable nucleic acid transcript library from mRNA in a sample of biological material.

Affymetrix has received US Patent No. 6,491,871 “System for determining receptor-ligand binding affinity.” The patent covers a system for light-directed spatially-addressable parallel chemical synthesis, a reactor system, photoremovable protective groups, data collection and handling techniques, and a technique for screening linker molecules.

Bio Merieux of Marcy l'Etoile, France, and Affymetrix have received US Patent No. 6,489,114, “Process for labeling a ribonucleic acid, and labeled RNA fragments which are obtained thereby.” The patent covers a process for labeling with signal amplification a ribonucleic acid (RNA), fragmenting the RNA to form RNA fragments, fixing a first ligand to a terminal phosphate located at least one of the 3' end and the 5' end of each of the RNA fragments, and binding labeling agents.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.